楊志云，首都醫(yī)科大學(xué)附屬北京地壇醫(yī)院中西醫(yī)結(jié)合中心主任醫(yī)師，教授，博導(dǎo)，科教處處長。北京市衛(wèi)生系統(tǒng)高層次人才，第六批全國老中醫(yī)藥專家學(xué)術(shù)經(jīng)驗(yàn)繼承人。從事中西醫(yī)結(jié)合肝病診療與研究20余年，在中西醫(yī)結(jié)合治療肝癌、肝硬化及并發(fā)癥、病毒性肝炎、脂肪性肝病等方面有豐富經(jīng)驗(yàn)。主要研究方向中西醫(yī)結(jié)合治療肝癌、肝硬化及并發(fā)癥、病毒性肝炎、脂肪性肝病等方面有豐富經(jīng)驗(yàn)。社會(huì)任職北京中西醫(yī)結(jié)合肝病學(xué)會(huì)秘書長中國醫(yī)師協(xié)會(huì)中西醫(yī)結(jié)合肝病學(xué)會(huì)常委獲獎(jiǎng)榮譽(yù)省部級(jí)以上獎(jiǎng)項(xiàng)3項(xiàng)科研成果近5年承擔(dān)國家及北京市自然基金3項(xiàng)。發(fā)表SCI論文18篇。授權(quán)發(fā)明專利1項(xiàng)。發(fā)表代表論文及著作：1.ZhiyunYang,LiWang,YixinHou,XianboWang.Effectsofmatrineonovalcell-mediatedliverregenerationandofRBP-JκandHES1[J].MolecularMedicineReports,2013,7(5):1533-15382.LinglingHe,XiaoliLiu,LijiaWang,ZhiyunYang.Thiazolidinedionesfornonalcoholicsteatohepatitis:Ameta-analysisofrandomizedclinicaltrials[J].Medicine,2016,95(42):e49473.XiaoliLiu,LinglingHe,JunyanHan,LijiaWang,MenggeLi,YuyongJiang,XianboWang,ZhiyunYang.Associationofneutrophil-lymphocyteratioandTlymphocyteswiththepathogenesisandprogressionofHBV-associatedprimarylivercancer[J].PLoSOne,2017,12(2):e01706054.LinglingHe,ShuanZhang,XiaoliLiu,YuyongJiang,XianboWang,ZhiyunYang.HbA1c-basedscoremodelforpredictingdeathriskinpatientswithHepatocellularCarcinomaandType2DiabetesMellitus[J].JournalofDiabetesResearch,2017,2017:38195025.LinglingHe,XiaoliLiu,YalinZhao,ShuanZhang,YuyongJiang,XianboWang,ZhiyunYang.Efficacyofnucleot(s)ideanalogstherapyinpatientswithunresectableHBV-relatedhepatocellularcarcinoma:asystematicreviewandmeta-analysis[J].DiseaseMarkers,2017,ID70759356.ShuanZhang,LinglingHe,XinhuiWang,ZhiboDang,XiaoliLiu,MenggeLi,XianboWang,ZhiyunYang,ANovelScoringmodelforpredictingmortalityriskinpatientswithcirrhosisandhepatorenalsyndrome[J].EuropeanJournalofGastroenterologyandHepatology,2018,30(8):938-943.7.XiaoliLiu,MenggeLi,XinhuiWang,ZhiboDang,YuyongJiang,XianboWang,ZhiyunYang.Effectofserumtriglyceridelevelontheprognosisofpatientswithhepatocellularcarcinomaintheabsenceofcirrhosis[J].Lipidsinhealthanddisease,2018,17(1):248.8.ZhiboDang,XiaoliLiu,MenggeLi,XinhuiWang,YuyongJiang,XianboWang,ZhiyunYang,ComparativeeffectivenessandsafetyoftraditionalChinesemedicinesupportingQiandenrichingbloodforcancerrelatedanemiainpatientsnotreceivingchemoradiotherapy:ameta-analysisandsystematicreview[J].DrugDesign,DevelopmentandTherapy,2019,13:221.9.LinglingHe,XiaoliLiu,ShuanZhang,MenggeLi,XianboWang,YuyongJiang,ZhiyunYang,Independentriskfactorsforpostoperative1-yearrecurrenceinpatientswithHBV-relatedhepatocellularcarcinoma≤3cm,GastroenterologyReport,accepted.10.XinhuiWang,XiaoliLiu,ZhiboDang,LihuaYu,YuyongJiang,XianboWang,ZhiyunYang*,Nucleos(t)ideanaloguesforreducinghepatocellularcarcinomainchronichepatitisBpatients:Asystematicreviewandmeta-analysis,GutandLiver,accepted.11.XiaoliLiu,MenggeLi,XinhuiWang,ZhiboDang,LihuaYu,XianboWang,YuyongJiang,ZhiyunYang*,EffectsofAdjuvantTraditionalChineseMedicineTherapyonLong-termSurvivalinPatientswithHepatocellularCarcinoma,Phytomedicine，accepted.承擔(dān)科研項(xiàng)目情況1.國家自然科學(xué)基金項(xiàng)目《苦參堿與肝卵圓細(xì)胞移植協(xié)同治療急性肝衰竭的實(shí)驗(yàn)研究》（編號(hào)：30873423）。2.國家自然科學(xué)基金項(xiàng)目《養(yǎng)陰扶正解毒方逆轉(zhuǎn)T細(xì)胞功能耗竭治療乙肝相關(guān)原發(fā)性肝癌的機(jī)制研究》（編號(hào)：81874435）。3.北京市自然科學(xué)基金項(xiàng)目《WNT信號(hào)通路在慢性乙型肝炎肝纖維化進(jìn)程中作用及涼血解毒方干預(yù)機(jī)制研究》（編號(hào)：7142081）。4.北京市科學(xué)技術(shù)委員會(huì)“首都臨床特色應(yīng)用研究”重點(diǎn)項(xiàng)目《基于綜合預(yù)警模型篩選養(yǎng)陰扶正解毒法降低小肝癌微創(chuàng)術(shù)后復(fù)發(fā)率的優(yōu)勢(shì)人群臨床研究》（編號(hào)：Z171100001017082）。獲得專利及成果專利名稱:用CD8陽性的T細(xì)胞上PD-1和TIGIT確定HBV相關(guān)原發(fā)性肝癌預(yù)后的系統(tǒng)專利號(hào)：201711436077.3...擅長：中西醫(yī)結(jié)合肝病基礎(chǔ)與臨床研究（中西醫(yī)結(jié)合誘導(dǎo)肝干細(xì)胞分化修復(fù)肝損傷）。主治病種：各種急性病毒性肝炎、慢性乙型肝炎、慢性丙型肝炎、自身免疫性肝炎、藥物性肝炎、酒精性肝炎、脂肪肝、肝炎肝硬化、原發(fā)性肝癌等